Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Lord Abbett

Lord Abbett Micro-Cap Growth Fund Class A (LAMGX)

Ticker LAMGX · · Holdings as of Jul 31, 2026

Expense ratio
1.37%$137/yr per $10k
5-yr return
+0.5%annualized
1-yr return
+4.4%as of Dec 2025
Net assets
$213.0Mall share classes
Holdings
86

Bottom line

Is LAMGX a good fund? The bottom line

LAMGX is the Class A share class of Lord Abbett Micro-Cap Growth Fund, an actively managed small-cap mutual fund from Lord Abbett.

It charges 1.37% — about $137 a year on every $10,000 invested, more expensive than 81% of small-cap funds we track.

It returned +4.4% over one year, +0.5% a year over five years, +13.7% a year over ten (as of Dec 31, 2025, per its prospectus).

With $213 million in net assets and 86 holdings, its largest position is Cogent Biosciences Inc (2.7%) and the top 10 make up 23.7% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.37%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year
  • High turnover (107% a year) can mean more taxable distributions

Updated Nov 19, 2026

What LAMGX invests in

The Funds investment objective is long-term capital appreciation.

Under normal conditions, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities of micro-cap companies. A micro-cap company is defined as a company having a market capitalization at the time of purchase that is under $1 billion or falls within the market capitalization range of companies in the Russell Microcap Index. The Fund uses fundamental analysis to look for micro-cap companies that appear to have the potential for more rapid growth than the overall economy. The Fund seeks to identify micro-cap companies that generally exhibit faster-than-average gains in earnings and that the portfolio management team expects to continue profit growth at a high level. The Fund evaluates companies based on an analysis of their financial statements, products and operations, market sectors, and interviews with management.…

From the fund's prospectus (filed Feb 25, 2026).

LAMGX performance

Fund calendar-year total returns, 2016–2025 2016: +2.1%; 2017: +38.4%; 2018: +2.7%; 2019: +34.6%; 2020: +79.4%; 2021: +3.5%; 2022: −29.3%; 2023: +5.9%; 2024: +26.9%; 2025: +10.7% +2% 2016 +38% 2017 +3% 2018 +35% 2019 +79% 2020 +3% 2021 −29% 2022 +6% 2023 +27% 2024 +11% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
LAMGX+4.4%+0.5%+13.7%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full LAMGX performance history →

What LAMGX costs

On a $10,000 investment, LAMGX's 1.37% expense ratio costs about $137 a year. The prospectus estimates $2,127 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full LAMGX fee table →

LAMGX top 10 holdings

#Holding% of fund
1Cogent Biosciences Inc2.75%
2Forte Biosciences Inc2.65%
3Adaptive Biotechnologies Corp2.62%
4Aehr Test Systems2.60%
5Navan Inc2.54%
6Enliven Therapeutics Inc2.34%
7Lindblad Expeditions Holdings Inc2.12%
8Fixed Income Clearing Corp.2.08%
9Fidelity Investments2.03%
10CECO Environmental Corp1.99%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 23.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to LAMGX

More funds like LAMGX →

LAMGX FAQ

What is the expense ratio of LAMGX?
LAMGX's expense ratio is 1.37%, which works out to about $137 a year for every $10,000 invested. The prospectus estimates total costs of $2,127 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LAMGX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.37%); 5-year return in the bottom quarter of its category; front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year; high turnover (107% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does LAMGX hold?
LAMGX's largest holdings are Cogent Biosciences Inc (2.7%), Forte Biosciences Inc (2.6%), Adaptive Biotechnologies Corp (2.6%), Aehr Test Systems (2.6%), Navan Inc (2.5%). It holds 86 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is LAMGX's 5-year return?
LAMGX returned +0.5% a year over the five years ending Dec 31, 2025, and +13.7% a year over ten years. Past performance does not guarantee future results.
Does LAMGX have a sales load?
Yes. LAMGX has a maximum front-end sales charge of 5.75%.
Who manages LAMGX?
LAMGX is offered by Lord Abbett through Lord Abbett Securities Trust.